You are here: Industry Insights > Market News > FDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

HydroLinX® Antifoam Emulsion

HydroLinX® Water for Injection in Bags

Crude Semaglutide

Clopidogrel Sulfate

Carbocisteine

HydroLinX® Buffer Solutions and Process Liquids

FDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards

biospaceNovember 17, 2017

Tag: Antibiotic , lupin

Favorites

Lupin Ltd., which makes generic antibiotics, antidepressants and heart medications for sale in the U.S., was warned by the Food and Drug Administration for repeatedly ignoring tests showing that pills made at two of its facilities didn’t meet quality standards.

In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the company chose to override the results. Lupin called the failed tests at the plant "laboratory error" even when evidence suggested that wasn’t the case.

Previous:Newly discovered ‘molecular guardian’ keeps cholesterol in check

Next:5 Deaths Force Acorda to Stop Enrollment in Phase III Parkinson's Trial

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

FDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Penicillin G BP/USP supplier Pharmaceutical API Antibiotic made in china

13-A1 13mm Bromobutyl Rubber Stopper for Antibiotic Vials, Injection

Vancomycin USP supplier Pharmaceutical API Antibiotic made in china

Cefatrizine propylene glycol JP 98%min supplier Pharmaceutical API Antibiotics made in china

Amoxicillin USP/EP 98%min supplier Pharmaceutical API Antibiotics Penicillin A broad-spectrum antibi

Cefixime USP 98%min supplier Pharmaceutical API Antibiotic made in china

Lincomycin hcl EP supplier Pharmaceutical API Antibiotics made in china

Alumina cover antibiotic aluminum cover

Dibekacin sulfate JP15 Pharmaceutical Antibiotics made in china

Mycophenolic acid 98.5%min HPLC Pharmaceutica Antibiotics Alkaloid made in china

FDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>